CD19-targeted CAR-T cells / Sinobioway - LARVOL DELTA

EECNTL: Study Evaluating the Efficacy and Safety With CAR-T for Recurrent or Refractory Acute Non T Lymphocyte Leukemia (clinicaltrials.gov) - P=N/A; N=72; Active, not recruiting; Sponsor: Sinobioway Cell Therapy Co., Ltd.; Recruiting ➔ Active, not recruiting; N=24 ➔ 72; Trial completion date: Nov 2019 ➔ Dec 2025

Clinical • Enrollment change • Enrollment closed • Trial completion date • Hematological Malignancies • Leukemia • Oncology

CAR-T Treatment for Relapse / Refractory Type Safety and Effectiveness of Lymphoma (clinicaltrials.gov) - P=N/A; N=6; Recruiting; Sponsor: Sinobioway Cell Therapy Co., Ltd.

New trial • Biosimilar • Hematological Malignancies • Lymphoma • Oncology